Immune cell profiles in the blood in children, adolescents and adults with tuberous sclerosis complex disease and their correlation with organ manifestations and treatment response to immunotherapy with mTOR inhibitors
Recruiting
- Conditions
- G40EpilepsyTuberous sclerosisQ85.1
- Registration Number
- DRKS00022991
- Lead Sponsor
- niversitätsklinikum Münster
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 90
Inclusion Criteria
Children and adults; clinically and / or molecular-genetic (from the blood) confirmed tuberous sclerosis with epilepsy.
Control group: epilepsy without evidence of tuberous sclerosis; People with no evidence of a neurological disease
Exclusion Criteria
Current immunotherapy except mTOR inhibitor therapy (everolimus, sirolimus) (control group of healthy people and people with epilepsy without tuberous sclerosis: also excluded when taking everolimus, sirolimus); current infection; comorbid autoimmune disease
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes in the immune signature of the blood in patients with tuberous sclerosis compared to patients with epilepsy
- Secondary Outcome Measures
Name Time Method Changes in the immune signature of the blood in patients with and without therapy with an mTOR inhibitor (everolimus, sirolimus)